A Phase II Open Label Randomised Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE)
Brief description of study
The primary purpose of the study is determine the safety and efficacy of olaparib alone, or combined with novel drug called AZD6738 in breast cancer patients. Olaparib is approved by the FDA for the treatment of certain types of ovarian cancer and breast cancer. We want to know if the drugs can repair damaged DNA and can kill cancer cells.
Clinical Study Identifier: s18-01646
ClinicalTrials.gov Identifier: NCT03330847
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
